NYSE:NVS

Novartis Ag Stock News

Healthcare > Drug Manufacturers - General

Buy NVS

*Your capital is at risk

$148.93

+1.85 (+1.26%)

At Close: Jun 22, 2026

First Look: iRobot Bankruptcy, Netflix-WBD Fight, Tesla Robotaxi

07:38am, Monday, 15'th Dec 2025

Stock News iRobot enters Chapter 11: iRobot (IRBT) filed for Chapter 11 and agreed to be acquired by contract manufacturer Picea Robotics, saying operations and

Cullen Capital Management LLC Has $253.74 Million Stock Position in Novartis AG $NVS

05:38am, Monday, 15'th Dec 2025

Cullen Capital Management LLC lowered its stake in shares of Novartis AG (NYSE: NVS) by 0.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities

Geneos Wealth Management Inc. Increases Stock Holdings in Novartis AG $NVS

04:09am, Monday, 15'th Dec 2025

Geneos Wealth Management Inc. increased its stake in Novartis AG (NYSE: NVS) by 52.4% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional inves

Balyasny Asset Management L.P. Increases Stock Holdings in Novartis AG $NVS

03:52am, Saturday, 13'th Dec 2025

Balyasny Asset Management L.P. boosted its position in shares of Novartis AG (NYSE: NVS) by 52.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchan

Novartis breaks ground on flagship manufacturing hub in North Carolina

07:00am, Friday, 12'th Dec 2025

East Hanover, December 12, 2025 – Novartis, a leading global innovative medicines company, broke ground yesterday on its more than 700,000-square-foot flagship manufacturing hub in North Carolina, m

First Look: Fed Cut Looms; SpaceX IPO; J&J Myeloma Data; Google Probe

07:37am, Wednesday, 10'th Dec 2025

Stock News Fed set for a âhawkish cutâ: The Federal Reserve is widely expected to deliver a third 25 bp rate cut amid sharp divisions over inflation vs. job

Market Today: Fed Cut Looms, Nvidia's China Shift, Target's SoHo Push, OpenAI Taps Slack CEO

05:34pm, Tuesday, 09'th Dec 2025

Stock News Fed set for âhawkish cut': Goldman Sachs (GS) and other Wall Street desks expect the Federal Reserve to deliver a third straight 25 bps rate cut wh

Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder

02:32pm, Tuesday, 09'th Dec 2025

Novartis AG (NYSE: NVS) on Tuesday shared results from the VAYHIT2 Phase 3 trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticost

Novartis Drops $1.7 Billion on AI Allergy Breakthrough

08:57am, Tuesday, 09'th Dec 2025

Novartis (NVS) is doubling down on AI-driven drug discovery with a deal that could be worth $1.7 billion, signaling rising conviction that data-intensive platfo

Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster

07:51am, Tuesday, 09'th Dec 2025

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) on Monday presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated chronic myeloid leukemia (CML) patients at th

First Look: Paramount's WBD bid, IBM-Confluent, Boeing-Spirit

07:37am, Tuesday, 09'th Dec 2025

Stock News Paramount goes hostile for WBD: Paramount Skydance (PSKY) launched a hostile, all-cash $30-per-share offer for Warner Bros. Discovery (WBD), valuing

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

07:30am, Tuesday, 09'th Dec 2025

Basel, December 9, 2025 – Novartis today announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) pre

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by